0001613103-20-000053.txt : 20201214 0001613103-20-000053.hdr.sgml : 20201214 20201214163113 ACCESSION NUMBER: 0001613103-20-000053 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20201209 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20201214 DATE AS OF CHANGE: 20201214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medtronic plc CENTRAL INDEX KEY: 0001613103 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36820 FILM NUMBER: 201386557 BUSINESS ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 01135314381700 MAIL ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Ltd DATE OF NAME CHANGE: 20150112 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Holdings Ltd DATE OF NAME CHANGE: 20140711 FORMER COMPANY: FORMER CONFORMED NAME: Kalani I Ltd DATE OF NAME CHANGE: 20140709 8-K 1 mdt-20201209.htm 8-K mdt-20201209
0001613103Medtronic plcD02 XH02false00016131032020-12-092020-12-090001613103us-gaap:CommonStockMember2020-12-092020-12-090001613103mdt:SeniorNotes2019Due2021FloatingMember2020-12-092020-12-090001613103mdt:SeniorNotes2019Due2022Member2020-12-092020-12-090001613103mdt:SeniorNotes2019Due20230.375PercentMember2020-12-092020-12-090001613103mdt:SeniorNotes2020Due2023Member2020-12-092020-12-090001613103mdt:SeniorNotes2019Due2025Member2020-12-092020-12-090001613103mdt:SeniorNotes2020Due2025Member2020-12-092020-12-090001613103mdt:SeniorNotes2019Due2027Member2020-12-092020-12-090001613103mdt:A2020SeniorNotesDue2028Member2020-12-092020-12-090001613103mdt:SeniorNotes2019Due20311.625PercentMember2020-12-092020-12-090001613103mdt:SeniorNotes2019Due20311.00PercentMember2020-12-092020-12-090001613103mdt:A2020SeniorNotesDue2032Member2020-12-092020-12-090001613103mdt:SeniorNotes2019Due20392.250PercentMember2020-12-092020-12-090001613103mdt:SeniorNotes2019Due20391.50PercentMember2020-12-092020-12-090001613103mdt:SeniorNotes2020Due2040Member2020-12-092020-12-090001613103mdt:SeniorNotes2019Due2049Member2020-12-092020-12-090001613103mdt:SeniorNotes2020Due2050Member2020-12-092020-12-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________________ 
FORM 8-K
 _____________________________ 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 9, 2020
 _____________________________ 
Medtronic Public Limited Company
(Exact Name of Registrant as Specified in its Charter)
  _____________________________ 
 
Ireland 1-36820 98-1183488
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices)
+353 1 438-1700
(Registrant’s telephone number, including area code)
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))












Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Ordinary Shares, $0.0001 par value per shareMDTNew York Stock Exchange
Floating Rate Senior Notes due 2021MDT/21New York Stock Exchange
0.00% Senior Notes due 2022MDT/22BNew York Stock Exchange
0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange
0.000% Senior Notes due 2023
MDT/23CNew York Stock Exchange
0.25% Senior Notes due 2025MDT/25New York Stock Exchange
0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange
1.125% Senior Notes due 2027MDT/27New York Stock Exchange
0.375% Senior Notes due 2028MDT/28New York Stock Exchange
1.625% Senior Notes due 2031MDT/31New York Stock Exchange
1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange
0.750% Senior Notes due 2032MDT/32New York Stock Exchange
2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange
1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange
1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange
1.75% Senior Notes due 2049MDT/49New York Stock Exchange
1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 09, 2020, Michael J. Coyle notified Medtronic Public Limited Company (the “Company”) that he would be retiring as the Company’s Executive Vice President and President, Cardiovascular Portfolio, effective December 31, 2020.

Item 5.07Submission of Matters to a Vote of Security Holders

On December 11, 2020, Medtronic plc, a public limited company organized under the laws of Ireland (the “Company”), held its 2020 Annual General Meeting of Shareholders in order to: (1) elect, by separate resolutions, twelve directors, each to hold office until the 2021 Annual General Meeting of the Company and until his or her successor is elected; (2) ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2021 and authorize, in a binding vote, the Company’s Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration; (3) approve, in a non-binding advisory vote, named executive officer compensation; (4) renew the Board’s authority to issue shares; (5) renew the Board’s authority to opt out of pre-emption rights; and (6) authorize the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares.

At the close of business on October 15, 2020, the record date of the Annual General Meeting, 1,345,239,472 Company ordinary shares were outstanding and entitled to vote. The holders of a total of 1,155,207,258 ordinary shares were present at the Annual General Meeting, either in person or by proxy, which total was not less than a majority of the issued and outstanding ordinary shares entitled to vote and thus constituted a quorum.

The final voting results and the votes used to determine the results for each proposal are set forth below:

1.The shareholders elected each of the twelve nominees to the Board of Directors, to hold office until the 2021 Annual General Meeting of the Company and until his or her successor is elected, as follows:

For
For (Percent of Votes Cast)
Against
Against (Percent of Votes Cast)
Abstain
Broker Non-Vote
Richard H. Anderson
970,524,752
93.630%
66,026,670
6.370%
2,966,120
115,689,716
Craig Arnold
1,023,126,829
98.515%
15,422,624
1.485%
968,089
115,689,716
Scott C. Donnelly
1,003,269,647
96.598%
35,330,535
3.402%
917,360
115,689,716
Andrea J. Goldsmith, Ph.D.
1,034,836,578
99.624%
3,905,019
0.376%
775,945
115,689,716
Randall J. Hogan, III
1,012,086,266
97.448%
26,504,473
2.552%
926,803
115,689,716
Michael O. Leavitt
1,019,110,953
98.127%
19,448,520
1.873%
958,069
115,689,716
James T. Lenehan
995,852,056
96.075%
40,679,072
3.925%
2,986,414
115,689,716
Kevin E. Lofton
1,036,854,816
99.835%
1,715,940
0.165%
946,786
115,689,716
Geoffrey S. Martha
971,226,971
94.037%
61,587,610
5.963%
6,702,961
115,689,716
Elizabeth G. Nabel, M.D.
1,037,429,259
99.873%
1,322,146
0.127%
766,137
115,689,716
Denise M. O’Leary
981,659,682
94.696%
54,982,953
5.304%
2,874,907
115,689,716
Kendall J. Powell
888,051,028
85.677%
148,461,395
14.323%
3,005,119
115,689,716











2. The shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2021 and authorized, in a binding vote, the Company’s Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration.

Votes
Percent of Votes Cast
For
1,090,245,797
94.465%
Against
63,879,176
5.535%
Abstain
1,082,285
Broker Non-Vote
NA


3. The shareholders approved, on a non-binding advisory basis, the compensation awarded to the Company’s named executive officers.

Votes
Percent of Votes Cast
For
949,563,754
91.727%
Against
85,645,061
8.273%
Abstain
4,308,727
Broker Non-Vote
115,689,716


4. The shareholders approved renewal of the Board’s authority to issue shares.

Votes
Percent of Votes Cast
For
1,027,827,893
98.980%
Against
10,595,010
1.020%
Abstain
1,094,639
Broker Non-Vote
115,689,716


5. The shareholders approved renewal of the Board’s authority to opt out of pre-emption rights.

Votes
Percent of Votes Cast
For
1,029,046,766
99.223%
Against
8,054,099
0.777%
Abstain
2,416,677
Broker Non-Vote
115,689,716


6. The shareholders approved authorization of the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares.

Votes
Percent of Votes Cast
For
1,021,355,109
98.598%
Against
14,527,390
1.402%
Abstain
3,635,043
Broker Non-Vote
115,689,716







Item 7.01Regulation FD Disclosure
On December 14, 2020, the Company issued a press release announcing the appointment, effective January 1, 2021, of Sean Salmon to succeed Michael J. Coyle as Executive Vice President and President of Medtronic’s Cardiovascular Portfolio. In addition, the Company announced that Mr. Salmon will continue to lead the Company’s Diabetes Operating Unit. These leadership changes become effective on January 1, 2021. A copy of the press release is furnished with this Form 8-K as Exhibit 99.1. Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.



Item 9.01Exhibits









































SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   MEDTRONIC PUBLIC LIMITED COMPANY
Date: December 14, 2020  By /s/ Bradley E. Lerman
   Bradley E. Lerman
   
Senior Vice President, General Counsel and Corporate Secretary





 EX-99.1 2 exhibit991-pressrelease121.htm EX-99.1 Document

image_01.jpg

NEWS RELEASE

Contacts:
  
Marguerite Copel
  Ryan Weispfenning
Public Relations
  Investor Relations
+1-203-214-8243  +1-763-505-4626

FOR IMMEDIATE RELEASE

SEAN SALMON NAMED EVP & PRESIDENT CARDIOVASCULAR PORTFOLIO;
CONTINUES AS EVP & PRESIDENT DIABETES OPERATING UNIT

DUBLIN – December 14, 2020 – Medtronic plc (NYSE:MDT) announced today that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1. Salmon will also continue to lead the Diabetes Operating Unit and continue to serve on the company’s Executive Committee. He succeeds Mike Coyle, who will leave Medtronic effective December 31 to accept a CEO role of a publicly traded company.

“We owe Mike a debt of gratitude for his significant contributions to Medtronic,” said Geoff Martha, Medtronic Chairman and Chief Executive Officer. “He’s played a vital role in our Cardiovascular portfolio, including overseeing the development and launches of numerous disruptive and life-saving technologies. On behalf of the Board, I would like to thank Mike for his leadership and wish him every success.”

“With 17 years leading several Medtronic business units, Sean is a highly respected leader both inside and outside of the company, with a proven track record of building and leading high-performing teams. I am confident in his ability to continue the turnaround of our Diabetes business, while ensuring continued growth and therapy adoption in our Cardiovascular portfolio,” said Martha.



Salmon joined Medtronic in 2004 and spent 15 years in increasingly senior management roles within Cardiovascular, including leading the Coronary and Renal Denervation, Peripheral, Cardiac Surgery, and Structural Heart businesses, before being named the leader of Medtronic Diabetes and a member of the Medtronic Executive Committee in 2019. While in Cardiovascular, he led Medtronic to leadership in drug-eluting stents, commercialized multiple product innovations in transcatheter aortic valve replacement (TAVR), and revitalized Medtronic’s renal denervation clinical program.

Salmon will continue his role leading the Diabetes turnaround and his role working closely with the other portfolio leaders and members of the Executive Committee on enterprise-level strategy and value creation under Medtronic’s new operating model. With his new additional Cardiovascular responsibilities, Salmon will oversee the Cardiovascular operating units, ensuring appropriate capital allocation to optimize Medtronic’s growth and profitability, overall business performance, and innovation designed to drive continued market expansion and increased share.

“I want to thank Geoff and the Board for this opportunity, which allows me to have an even greater impact on improving more patients’ lives,” said Salmon. “Over the past year, we’ve taken a number of bold steps to improve our Diabetes performance and competitiveness, including the appointment of a new leadership team, accelerating R&D investment, entering the smart pen market, and making significant progress on our customer-centric pipeline of products and services. Completing the turnaround in Diabetes remains a high priority for me. And, I’m excited to reunite and work with the exceptionally talented leaders of our Cardiovascular operating units as we continue the momentum behind Mike’s vision of growth and innovation to deliver meaningful and life-enhancing cardiovascular technologies.”

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic


employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

 EX-101.SCH 3 mdt-20201209.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 mdt-20201209_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 mdt-20201209_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 mdt-20201209_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 0.000% Senior Notes due 2025 Senior Notes 2020 Due 2025 [Member] Senior Notes 2020 Due 2025 Entity Address, City or Town Entity Address, City or Town Entities [Table] Entities [Table] 1.375% Senior Notes due 2040 Senior Notes 2020 Due 2040 [Member] Senior Notes 2020 Due 2040 1.50% Senior Notes due 2039 Senior Notes 2019 Due 2039, 1.50 Percent [Member] Senior Notes 2019 Due 2039, 1.50 Percent [Member] Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover page. Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type 0.375% Senior Notes due 2023 Senior Notes 2019 Due 2023, 0.375 Percent [Member] Senior Notes 2019 Due 2023, 0.375 Percent [Member] Entity Emerging Growth Company Entity Emerging Growth Company 1.75% Senior Notes due 2049 Senior Notes 2019 Due 2049 [Member] Senior Notes 2019 Due 2049 [Member] Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag 1.625% Senior Notes due 2050 Senior Notes 2020 Due 2050 [Member] Senior Notes 2020 Due 2050 Trading Symbol Trading Symbol Floating Rate Senior Notes due 2021 Senior Notes 2019 Due 2021, Floating [Member] Senior Notes 2019 Due 2021, Floating [Member] Document Period End Date Document Period End Date 0.375% Senior Notes due 2028 2020 Senior Notes Due 2028 [Member] 2020 Senior Notes Due 2028 Entity Information [Line Items] Entity Information [Line Items] Entity Registrant Name Entity Registrant Name 0.000% Senior Notes due 2023 Senior Notes 2020 Due 2023 [Member] Senior Notes 2020 Due 2023 Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Ordinary Shares, $0.0001 par value per share Common Stock [Member] Class of Stock [Axis] Class of Stock [Axis] 0.25% Senior Notes due 2025 Senior Notes 2019 Due 2025 [Member] Senior Notes 2019 Due 2025 [Member] Entity Address, Country Entity Address, Country 1.00% Senior Notes due 2031 Senior Notes 2019 Due 2031, 1.00 Percent [Member] Senior Notes 2019 Due 2031, 1.00 Percent [Member] 0.750% Senior Notes due 2032 2020 Senior Notes Due 2032 [Member] 2020 Senior Notes Due 2032 1.625% Senior Notes due 2031 Senior Notes 2019 Due 2031, 1.625 Percent [Member] Senior Notes 2019 Due 2031, 1.625 Percent [Member] Local Phone Number Local Phone Number 2.250% Senior Notes due 2039 Senior Notes 2019 Due 2039, 2.250 Percent [Member] Senior Notes 2019 Due 2039, 2.250 Percent [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code 0.00% Senior Notes due 2022 Senior Notes 2019 Due 2022 [Member] Senior Notes 2019 Due 2022 [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Class of Stock [Domain] Class of Stock [Domain] 1.125% Senior Notes due 2027 Senior Notes 2019 Due 2027 [Member] Senior Notes 2019 Due 2027 [Member] Country Region Country Region EX-101.PRE 7 mdt-20201209_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 image_01.jpg MDT LOGO begin 644 image_01.jpg MB5!.1PT*&@H -24A$4@ KT !S" 8 "56;HU 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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mdt-20201209_htm.xml IDEA: XBRL DOCUMENT 0001613103 2020-12-09 2020-12-09 0001613103 us-gaap:CommonStockMember 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due2021FloatingMember 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due2022Member 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due20230.375PercentMember 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2020Due2023Member 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due2025Member 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2020Due2025Member 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due2027Member 2020-12-09 2020-12-09 0001613103 mdt:A2020SeniorNotesDue2028Member 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due20311.625PercentMember 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due20311.00PercentMember 2020-12-09 2020-12-09 0001613103 mdt:A2020SeniorNotesDue2032Member 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due20392.250PercentMember 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due20391.50PercentMember 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2020Due2040Member 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2019Due2049Member 2020-12-09 2020-12-09 0001613103 mdt:SeniorNotes2020Due2050Member 2020-12-09 2020-12-09 0001613103 Medtronic plc D02 XH02 false 8-K 2020-12-09 L2 1-36820 98-1183488 20 On Hatch, Lower Hatch Street Dublin 2 IE 353 1 438-1700 false false false false Ordinary Shares, $0.0001 par value per share MDT NYSE Floating Rate Senior Notes due 2021 MDT/21 NYSE 0.00% Senior Notes due 2022 MDT/22B NYSE 0.375% Senior Notes due 2023 MDT/23B NYSE 0.000% Senior Notes due 2023 MDT/23C NYSE 0.25% Senior Notes due 2025 MDT/25 NYSE 0.000% Senior Notes due 2025 0.000% Senior Notes due 2025 MDT/25A MDT/25A NYSE NYSE 1.125% Senior Notes due 2027 MDT/27 NYSE 0.375% Senior Notes due 2028 MDT/28 NYSE 1.625% Senior Notes due 2031 MDT/31 NYSE 1.00% Senior Notes due 2031 MDT/31A NYSE 0.750% Senior Notes due 2032 MDT/32 NYSE 2.250% Senior Notes due 2039 MDT/39A NYSE 1.50% Senior Notes due 2039 MDT/39B NYSE 1.375% Senior Notes due 2040 MDT/40A NYSE 1.75% Senior Notes due 2049 MDT/49 NYSE 1.625% Senior Notes due 2050 MDT/50 NYSE false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document And Entity Information
Dec. 09, 2020
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Dec. 09, 2020
Entity Registrant Name Medtronic plc
Entity Incorporation, State or Country Code L2
Entity File Number 1-36820
Entity Tax Identification Number 98-1183488
Entity Address, Address Line One 20 On Hatch, Lower Hatch Street
Entity Address, City or Town Dublin 2
Entity Address, Country IE
Entity Address, Postal Zip Code D02 XH02
Country Region 353
City Area Code 1
Local Phone Number 438-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001613103
Ordinary Shares, $0.0001 par value per share  
Entity Information [Line Items]  
Title of 12(b) Security Ordinary Shares, $0.0001 par value per share
Trading Symbol MDT
Security Exchange Name NYSE
Floating Rate Senior Notes due 2021  
Entity Information [Line Items]  
Title of 12(b) Security Floating Rate Senior Notes due 2021
Trading Symbol MDT/21
Security Exchange Name NYSE
0.00% Senior Notes due 2022  
Entity Information [Line Items]  
Title of 12(b) Security 0.00% Senior Notes due 2022
Trading Symbol MDT/22B
Security Exchange Name NYSE
0.375% Senior Notes due 2023  
Entity Information [Line Items]  
Title of 12(b) Security 0.375% Senior Notes due 2023
Trading Symbol MDT/23B
Security Exchange Name NYSE
0.000% Senior Notes due 2023  
Entity Information [Line Items]  
Title of 12(b) Security 0.000% Senior Notes due 2023
Trading Symbol MDT/23C
Security Exchange Name NYSE
0.25% Senior Notes due 2025  
Entity Information [Line Items]  
Title of 12(b) Security 0.25% Senior Notes due 2025
Trading Symbol MDT/25
Security Exchange Name NYSE
0.000% Senior Notes due 2025  
Entity Information [Line Items]  
Title of 12(b) Security 0.000% Senior Notes due 2025
Trading Symbol MDT/25A
Security Exchange Name NYSE
1.125% Senior Notes due 2027  
Entity Information [Line Items]  
Title of 12(b) Security 1.125% Senior Notes due 2027
Trading Symbol MDT/27
Security Exchange Name NYSE
0.375% Senior Notes due 2028  
Entity Information [Line Items]  
Title of 12(b) Security 0.375% Senior Notes due 2028
Trading Symbol MDT/28
Security Exchange Name NYSE
1.625% Senior Notes due 2031  
Entity Information [Line Items]  
Title of 12(b) Security 1.625% Senior Notes due 2031
Trading Symbol MDT/31
Security Exchange Name NYSE
1.00% Senior Notes due 2031  
Entity Information [Line Items]  
Title of 12(b) Security 1.00% Senior Notes due 2031
Trading Symbol MDT/31A
Security Exchange Name NYSE
0.750% Senior Notes due 2032  
Entity Information [Line Items]  
Title of 12(b) Security 0.750% Senior Notes due 2032
Trading Symbol MDT/32
Security Exchange Name NYSE
2.250% Senior Notes due 2039  
Entity Information [Line Items]  
Title of 12(b) Security 2.250% Senior Notes due 2039
Trading Symbol MDT/39A
Security Exchange Name NYSE
1.50% Senior Notes due 2039  
Entity Information [Line Items]  
Title of 12(b) Security 1.50% Senior Notes due 2039
Trading Symbol MDT/39B
Security Exchange Name NYSE
1.375% Senior Notes due 2040  
Entity Information [Line Items]  
Title of 12(b) Security 1.375% Senior Notes due 2040
Trading Symbol MDT/40A
Security Exchange Name NYSE
1.75% Senior Notes due 2049  
Entity Information [Line Items]  
Title of 12(b) Security 1.75% Senior Notes due 2049
Trading Symbol MDT/49
Security Exchange Name NYSE
1.625% Senior Notes due 2050  
Entity Information [Line Items]  
Title of 12(b) Security 1.625% Senior Notes due 2050
Trading Symbol MDT/50
Security Exchange Name NYSE

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ż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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 18 96 1 false 17 0 false 0 false false R1.htm 0001001 - Document - Document And Entity Information Sheet http://www.medtronic.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports mdt-20201209.htm exhibit991-pressrelease121.htm mdt-20201209.xsd mdt-20201209_cal.xml mdt-20201209_def.xml mdt-20201209_lab.xml mdt-20201209_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mdt-20201209.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 18, "dts": { "calculationLink": { "local": [ "mdt-20201209_cal.xml" ] }, "definitionLink": { "local": [ "mdt-20201209_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "mdt-20201209.htm" ] }, "labelLink": { "local": [ "mdt-20201209_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mdt-20201209_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mdt-20201209.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 45, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 16, "memberStandard": 1, "nsprefix": "mdt", "nsuri": "http://www.medtronic.com/20201209", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mdt-20201209.htm", "contextRef": "i9745ebdc22324aa8b963a45673f5d758_D20201209-20201209", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document And Entity Information", "role": "http://www.medtronic.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mdt-20201209.htm", "contextRef": "i9745ebdc22324aa8b963a45673f5d758_D20201209-20201209", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 17, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region", "terseLabel": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "mdt_A2020SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Senior Notes Due 2028", "label": "2020 Senior Notes Due 2028 [Member]", "terseLabel": "0.375% Senior Notes due 2028" } } }, "localname": "A2020SeniorNotesDue2028Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_A2020SeniorNotesDue2032Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Senior Notes Due 2032", "label": "2020 Senior Notes Due 2032 [Member]", "terseLabel": "0.750% Senior Notes due 2032" } } }, "localname": "A2020SeniorNotesDue2032Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2021FloatingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2021, Floating [Member]", "label": "Senior Notes 2019 Due 2021, Floating [Member]", "terseLabel": "Floating Rate Senior Notes due 2021" } } }, "localname": "SeniorNotes2019Due2021FloatingMember", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2022 [Member]", "label": "Senior Notes 2019 Due 2022 [Member]", "terseLabel": "0.00% Senior Notes due 2022" } } }, "localname": "SeniorNotes2019Due2022Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20230.375PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2023, 0.375 Percent [Member]", "label": "Senior Notes 2019 Due 2023, 0.375 Percent [Member]", "terseLabel": "0.375% Senior Notes due 2023" } } }, "localname": "SeniorNotes2019Due20230.375PercentMember", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2025 [Member]", "label": "Senior Notes 2019 Due 2025 [Member]", "terseLabel": "0.25% Senior Notes due 2025" } } }, "localname": "SeniorNotes2019Due2025Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2027 [Member]", "label": "Senior Notes 2019 Due 2027 [Member]", "terseLabel": "1.125% Senior Notes due 2027" } } }, "localname": "SeniorNotes2019Due2027Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20311.00PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2031, 1.00 Percent [Member]", "label": "Senior Notes 2019 Due 2031, 1.00 Percent [Member]", "terseLabel": "1.00% Senior Notes due 2031" } } }, "localname": "SeniorNotes2019Due20311.00PercentMember", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20311.625PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]", "label": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]", "terseLabel": "1.625% Senior Notes due 2031" } } }, "localname": "SeniorNotes2019Due20311.625PercentMember", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20391.50PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2039, 1.50 Percent [Member]", "label": "Senior Notes 2019 Due 2039, 1.50 Percent [Member]", "terseLabel": "1.50% Senior Notes due 2039" } } }, "localname": "SeniorNotes2019Due20391.50PercentMember", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20392.250PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2039, 2.250 Percent [Member]", "label": "Senior Notes 2019 Due 2039, 2.250 Percent [Member]", "terseLabel": "2.250% Senior Notes due 2039" } } }, "localname": "SeniorNotes2019Due20392.250PercentMember", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2049Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2019 Due 2049 [Member]", "label": "Senior Notes 2019 Due 2049 [Member]", "terseLabel": "1.75% Senior Notes due 2049" } } }, "localname": "SeniorNotes2019Due2049Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2020Due2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2020 Due 2023", "label": "Senior Notes 2020 Due 2023 [Member]", "terseLabel": "0.000% Senior Notes due 2023" } } }, "localname": "SeniorNotes2020Due2023Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2020Due2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2020 Due 2025", "label": "Senior Notes 2020 Due 2025 [Member]", "terseLabel": "0.000% Senior Notes due 2025" } } }, "localname": "SeniorNotes2020Due2025Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2020Due2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2020 Due 2040", "label": "Senior Notes 2020 Due 2040 [Member]", "terseLabel": "1.375% Senior Notes due 2040" } } }, "localname": "SeniorNotes2020Due2040Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2020Due2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2020 Due 2050", "label": "Senior Notes 2020 Due 2050 [Member]", "terseLabel": "1.625% Senior Notes due 2050" } } }, "localname": "SeniorNotes2020Due2050Member", "nsuri": "http://www.medtronic.com/20201209", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Ordinary Shares, $0.0001 par value per share" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 18 0001613103-20-000053-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001613103-20-000053-xbrl.zip M4$L#!!0 ( .:#CE&XG3(:Q L !TN > 97AH:6)I=#DY,2UPJNJ$=I?OR^K6@?7'#;&1'CF R/H.K(R7[Y\6:W#?QX/^Z-? MS@=BZK)4G+__\=U)7VS4F\VKK7ZS>3PZ%F]'I^]$I]%JBY&1N55.Z5RFS>;@ M;$-L3)TKNLWF;#9KS+8:VDR:HXLF+]5IIEI;:L0NWC@ZY+_@)\GXZ!^'_ZS7 MQ;&.RHQR)R)#TE$L2JORB;B*R5Z+>KT:U=?%W*C)U(G-UF9+7&ESK6YD>.Z4 M2^EHLWM[OV[MPLHFQH=)ULU3^F$C4WE]2FQ =W>S< A091,A4P9-),8,-8.Z>S[C9,N"'C5"33NDS5).\ZNG75X\JZK=9.MUL[._OX!/ZDG,E/IO/OM($F,_+9F 9FZ):.2\-BJ M_U&WS<[TO\["83NMUD&J]R\*46/GZLHT,GQRDM MYHZUB*'SSI[C=;^WI./6XWVD\\^MNSFUI^R;+NQW^D\O[&;C<[.TX_7EVUZ_P8? M(XRVD/D/&UO+I"ID'(-@NBW1+MS:>A\9NEG<\N"#-8"EE#P,NB[6R>!!9O"_ M9\Z,8%),D3:2V;A;YH QC]HXZF.NC)S]YLWVWL$]4GJV,P>,/\4%#T\\4AE9 M<48S<:$SF3]Q]KU/'=TGTC=OVCNM@_!S>;Y/G^Q.X"NPW&/<=L>/>#8 O<#0 MOQ/J-XY.0< EICIB94#I5WC_OK"]7,0NYC(75X1JFE">P] [1_I[H?>\'*4>M*V7]'[VM%[DM^0==J$\SP,W"O \,LYX]_M^F9KJ[[9[M3W-CM;SQ_= MK[A]QE#M[FS5MUO;]<[.YLY#O#9]0W.G+_I8S_1G6+[[J.4_#2_$R>GIX/BD M-QH\V?I]8>,:4>[(_$D1>/PF;CLO3L=GHFS'LXC!A_.Q3=OMO8.Q/G% MX/+D>' V$OW>Q?')\$/OLO_^7>]"G \O1C\-WYT,H=WW#U[IR?K#L]')V?O! MI>A=/GHHA.['P0C/A^>#BQ[&_BS>GYV,%L?Y3$M[1LGTCV6!^"+)X4WK21-YZ?0(\C>6Q'D^*=(92,??QVSVP:P?HZRQ3SA$UQ%L2MHPBHMB* M4W7-SQ#:FIA-=3 *-F#&*A2K4RRALM7FO256*6"2Z ^&PN@4=B3XK?!*,T6 MC(PI7EC5> 4)\3CLV%^;K8,KV#^CX!,I8AH[/L^$O>_*F$2BC9@J*RRX3R4H ML'Q_C,6-&I=>F;%/EFZK^5617U:J6/Q,.DD$.DB MK;FV_Y4*@/YX./:GRI* MUH(V3+ +F8:H#'Q+R\CR]2!<*\6-YT*6YC\9B@<8:!D1IR^#4HFN8( MT421;8AACB2:RC3AZ;S\CQHFU<2)F.DRY9G7'KIP17X=W+UP+<,?EDU5X?>8 M*3O%WS,!^Y \'K;6-BK/OGH\*3<5[5TQ)VG"T=A7EL^"D*TP,.:7#SB7*)'@ MMA8H#8?[R==.O^Y\G>5<$AIM@ ):1#O MG-,QNL9BD38Q#QV7*O4F^7!6YO&6=5 .(I*%T,H,,3T1,F.P)X$ 34.EQRK M5+DY!W/%23# E2:7 $WN]V%0+NEL<5CF&P704FY+PQLM%HB1<7K&=N>>"8TL MYD+&NN 4^R3&[R1=2+!.SNM'WE_.MU10Y MMCHMW<,IGWAY$WY.S4KS3Z@^-B2OZS*!ZNK*=";G=N/97QB]7)I4A? WC2?Q M6CX@QINM5L<# ,"'.>WM*HD4(X#?V?'K.F2&I5R!.D"@<(^G+V9"ZX&/L7=A MLDZ "[@S6OL:^W)QY@TO*$=R'E..NNK[[9HXQ_$*!F):E7H9B+N@*WK3*9*3'ZN#+).%%IC7L MD:H>?-;>;X@KGU6/G-WON>[F2FU4=(L9L2DG=0)8/4TY>!/F@TO _Q'D,"(; MBZQ,G2JP S@EQJ$Q+]?!43XZCM_11A(& Z-":FY$Q8U,8:PA%*TH1.F[4>_# MQ??!>X9\#?/++ZU;%CKCXQ&OXB$B((F[6S8!Q3E[O;IB7>DM^9%YTY?K=0@N M([_&G.R;Y> 9OWMFEDRU)0#?,SO/U$R1*P)4-\%&^F"C.F77'55(E9.K=B:L-J\JY+":R #AP)IQ#1++P&DFFJ8[" M*0!]KB<98OG(6=;J#U9),#F4N9JW!"U&*W MKTI<)LTU.4&W!7^E0>?57,]L>&RGTM 7ME^?=Q_UF;(6$ %7(/)"X27N;'""^3L#3![1W@$_"YU^Q"P\785TCI?R6#&0LMC:R>O ML;%DJ5T1_EBG_+*9"M]3! /HKI!:@U[5%&8%H5.!-4%?K8H=;XV,0)UUGGU] ME\8YN<;_K/-JOJ-+%TEUX>]6CK$0WT-GOM7U9+%8TV9<[%"A*SR'%,BD9ZKU M+LDS->>+#O(M*BUD$G_U@;A]0K>O"N)8LVE590D4QNTM>B H4' 6ZHY;[+U& ME"@[2Z\8RB2$<:6=L1;D 2M4QD*&YK>7,FVE<#_.34)"E-!=E9QI]FF9<;>DL"MW0DL2NE&>%WP# MNJ2C-79A4B&&'I]+\KNMI$Q7C1GE2(O(5XR[=MUIU5Y/(_783=7'OF?0&Z/G M67'W7TI)]RZM/L';2?+,!GS,3?S%N&QA7@,4\?)W>M^S])3Q?TMP!1D*Z>]6W!#"X?,$.@2JXS_(Z-/2_ M /CRCA.9"Y49\K&0O+7QK]9\QTLRK?(+CJ0\] =(HD :T"!^468FTBQ]*]I9 MFMI8$]5?^\F_KI\D% @]MZ%*LRP0^ZT:-EK$S0<+1Z *.(R%Z=PJ-#5V@$:9/XJ30L[FMBI"?$GUZ#*GO\M4PO]R5VAEI33[4. M L!!1V7>AWP:6XY_H\A+-O0:U\'+?)UO'!*2=3_?[TVY4#J$@B\E;634.##& M,L.^]; M4[)H:0$:.1>Q2A*NIZS_E"_VB=$9ED 3JPK_/>%J^.^[4WJI5V>/IPU]:U?;R++V]_,K]++?LT]FO9;IJ]1-9CB+ 9)A=FPR MQ$DV?)G5ZFYA@6QY2W*X_/JW6K;!@&WNX::L%<"6U.JN>KKJJ>K;K_][W$N] M'S8ODJS_VQ)NHB7O?U=__3^^_^_?=SYY&YD>]FR_]-9SJTIKO*.D['K?C2T. MO3C/>M[W+#],?BC?KYY9SP8G>;+?+3V""+IT,5_A+-:&FYZA=QEO=4"3IT5>4^(CX) M)H7 G8?SFH7HLKL*L>L9>JEMA=7,_^[$,%USITD?8IWAR^[#P]Y4:G#T2 MJR*J"A]?F/'(\94:75"(NSHE !_>?^'F27VNDX&8?B4T)%D@A,LZZIF+@N]9 M4^99/]%-G?66';H!I;*Z>R55_?W?EFS?__IE"2!GE5G]M6=+Y;GG??N?8?+C MMZ7UK%]"1_([)P-XB1Y]^FVIM,?EKOYKDAU>4)ZG];A,^>)'KW^N-RQ\6]+B0P9MY'1A%#"E!*1#*AB/ AIS$W(Q=\;DZKXY^WN MJYY[M4U6-OM0OY-U:$VNTJV^LOH M$VVGNZ?9\>[IX7'K=.VT#=>V.[MH]^ KWO[>.FYO?.BUR1;=_;Z7;G>^HM8' M@3Z1O9/=[SK8_KYYW#[5IU FV^WMI.V/?['6P2&\-SW8[9BTW=DZ;G<^'+0Z M^S_,QP])]/%KT/Z^27?)AX.][UOP+JC#QK?#O8TTV25[W=V.1GN==K*]L7O2 M_M@:/_,-WL7[>YT,0YD'N]^AO@?0KLXA:G_?.=S^_N?!7N]#MWVZD[;(%FL? M;*%=+$X^=3;+UA=T_*FS]G=(><#C,/9C&VJ?:1[Y,HIB7T>1X PT:(186D5@ M5@),,:*_+E_0Y^.K=\?N)X7K9&4;KM3:O4Z[I]/:Y01TJRSSM0*GQD(";H]$ MH1^(B"A!(BE"LK3:FE@8;Y#JGZ[@-6-R6Q2?,S"#Z5XR6,],K>9KU8RFU:P0 MUR+$UK>$?:H(T)S;VJ0G8F?UO? M^M=%IW;YX=7)5Q=+'X!X,S/Y! 8K+S<@.%EUE?(Q\1UGNGSMK)IFSJV3*Y// MDY=0QTC%@=*8* G3,L *48%BE^I?@D:Z_JTTD_#5^C3F5@HH!J'8,+94A%@JF0@+ C M$V@F6/1Z=+KFZC^EV)%2Q6M4*L$FCH'L2JO ^)I J(C%*HBMD5)C3E^/4F=U M5(IQ,R"OF03C, X#:B@*#69Q+ 75% -;PK&,5(C-Z]],FTQ?96*"8B+"(!:61(H%7$I!A(PCB>,H)/HU M.=J9?5:2)N&ON=-:"218$Q* GV4D- HLL4;4$,9 W_B5DV,J;2,=8 MTHBHD&$L11QP$PNN(QU*0E^K>L?Q+$.O4:"5YXJ9?(TZQ0I(DA%"$(J9D8% 1D:8Q IK1E04O%*=COLI?_G]=/GBO(3E MJ?F+RR;Y,9KJ.%+U-1-^_\9+T\^,IT?VDK[?M6Y2\@HCS9 /RO='B2F[*QBA M_UZJ;EW]M1BH_NJO4;X,!8S^'I5SI30W&=6'>N=*ERO%L-=3^1*/;BR24[N"!;RE^G@T:E@(Y;BYL).& LJA:5_; M6YW-#>]+9ZVS^>5BNZ9:]%QJ^V5S_>O.5F=K\XNWUM[P-O^]_L=:^^.FM[[= M:FU]^;*UW7[")I ;->&[*KI)?[_,^@UOH[G>_.<_<(#>0R]E\DK='[B&\E(% MV<8[?9*'&:'KY4T[Q.YY, M\8,RT5YO\VBO\Y5M=_:/VAM_\1;9@FN[1ZV/>P?PCJ/MCYM'+?+7#_/Q&S-_ M_)GND?1'=)#A=F>GM]OY/6UW]OGVQAIJ;QR>[A[\V=T[6#O:Z[5[>YTUMMM9 M.]V#][4Z7_]&,0UX"+)AB B?84U]83'S=M[3=8:[ M=-FZ-U[3)':CW@B>9F>SW?%V-C]O[W2>3^UOYF8^#_-BJ/JE5V;>%ZO=BI>1 M&C#ULMS#_)WYQK@//:HO3L#ZB>EU>7K?EEY7$Z]LWD__#^:+0""YX^ M+E>,"V:@Q*Y1)R?0?MN?Y:\^5U'!YBA6>%N.ZV1[0__-0XR#(+ ^#V3D,XJE M6QM"_8C&DN P%B*, %96CZ)&V:A65M[DE;LWN>M:#ZIP\(]H_NP'O-H\AJO;<"K.1#9VL.?-4X7T96.WR*\9+ M^EY2%MYZ5X$)S7^YB9J"YP;]E]D!GH&MF*?E*"O+K.<4#6HM593:R0U1EAN; M^U#;5 T*NS+YX_UDW>QH&;%?/?3^A\W+1*MTC!0 SSA;)&53<.H21F4._\VD M^'$NJ5GEDI9+<_4:0Y%W'E-TP;*F*2_OT(&QQZ> M90AG@/[G>X!1,O81":G+W*Y8LZ_R09[]T-FP7^8G%TGI9I45W^KK+ =^7FTE M4.7DUTMP^W3GV-S[U]C:^LM8W MX99-GB]]YHBS D_8I'PF5L.&\7:^+%@"E&X0F*RM+J5VU3US=4%E&.;/[\[ M+,!V:N/R,K)'7N*AP7TY WC%CZ$9?NQ.;7KU_?5R7_R0I!9*A]"G[G@WZ'A; MY^N6!4,FC*RON)$^XV'DRP Q/PICQ D.0L7HTBKV:2"NAI-UQWOS':^CCK?& M0]JZBB 9,A=SG)E8^(U3[ EGF8\TI9E09PN32JA0^QH(R M(19VQ+O3O(4]\FQ METSSQTOIB=JBOE1,NFT/DJ)X 1!TG,D;F>L:?:\$?5L[7[S-WB#-3MQ- MOXN\P6MGS5DPK+S9W2-?WV""N 7R32K:Y86B7(V^Y[?ZA2=QO>I^P(:$3U MP?M2YM:6SV@:R#-#USK\N9UWLJ/^6\-6I_6WX)* <(P?<051L^3:EU91'S-D MM868VEJVM+KAAM?ZWI4MW!J/.J!>Y2_':4NGNUFIRXD.1W>].07JOQ'%@L0B MAH"*8Y\9'OC*@H5@EL1:DTC@@,[--SXG(S![+,Q[-]:P&Q\=Y!!I) .5>O;8 MZF&9_'##IN!W;7&C0='GY#O_WR.:MW%O<,/)V1LS:KBU\=??<4RE93;T#8X# MM[FL\$44A;X.$+&(F"@66NFL_1U8A8G; MO!53()2,$>4K8D+?:A!F9)05/%A:9< ],:CHUI.PQG,4Q)/8W7D.Y7R6S3__ M(0@.WQ=>:5,[<$#P^A42&BZEE0Y=+.TIZ+, .V.O=3'G,S)FMO:1YFBPT4R+ MV\[1D*(IT?S+]YQ(\- #](^3?;GAT$,[*[VU@5MEYI3Q0!GJ)VWG[#33!Z#> M$#7VJ]EH><7$X:,:\2_H$K$WFJX,4('N8;U4%9.)O=Y5J5S)=,R>R/Q$9F"] M:_6AY^9CJ\$@SX!9N@1\E!U[D4VS(]=8=]&)Q!/^O[PX29TQ2 JP#*7M&Q!" MF8$<>L.T5'V;#8OTQ"M4F13Q2?7D^($, J?]45HH&Q69GT_R&T(Y(.#^R>1: M#%8@.W+/N1D;B"(8:X8\>/ Y4)(V$6,/8;INF2^]U>CG&D J];[V M$^<[O-:7^_7-1X^SHRQ+(P7P*Z$33+.D[WE2 N+=:,"P/TYQ%B^2*HU&1;>_ M?^CMDM;1WD9ZN LTJ;T!]>MMXCTW6OJQA=L'?['VJ>:[O:W+HZ(_K[ MX?;WG>[VQB%J=0[);N?;X>Z!/MH]_4K:&_NT?9HFNZDXFIX49#F1QB#M\U H MGXF ^))IZ<>!)=1RJD*)7)H?-,G>/_[0-IM;W[ S! M@#'"Q];QTI(9MU+F'0Z]]0\[GML*%F[\Y0:^YS99]MJ>UO;T$>WIEZS:KL!M M. Z4PS7J!1O3U@:\9V,3XDRH\[ MWZ\8TR-HTU&K\Q=J.^/9:2&(3I/=SN[1;N\ONK?1[K8V=O%NI]V]8DPC$FBI M8Q_%S$WTHI&O# Y\03A!R HA0_DFC.DYDKS>&$I7+2EFRL=DRIA>6'1X9DH9 M]/+JSMJ:UM;T!5G3S[EUS-0=^%)M!N!"LWP[CE]H-F]D5?<^[@&]7#MM'1R> M;&]L JUT$_6V\.[I+M[[OD6W/^XDV]_WP$+N7[*J@T-X%X,VG6QWME@+ZN@F MZNT>?#MH'WQ+@:8RH+GY"6-\^@+(/NMWVQP_N_;AU=9+T2>MT_VB7[++6P5;5EMW> M-WMP]^3]NG0*I[ MWPY;WS>AC*^7R374;Z>[U]D];76^DG9O%]KRE4 [2>OC5PJD^F3O^U_'NYT_ MNWN7%N '411B;(S/.*,^"R(-C %^4 9RIIQP4,?2ZG8.8%/YB?>EJW);-+S_ MBYJ &.P-5.[]4.G0>@.W+;*[>@<&7B/])D@?V]"1":UA?@.8GQ_3;;BB,3;< MYS(.?488]Z-8&M]RQ"));"!8N+3:VNC4Z'U0]%[97P5\X]7%"1,;/@E.G3NM M 7X#@$_MYV $%6' ?4N-]AFCR(^"F/M&"ZR(Y4)J##P%8+*;Y8=>M77\63+@ MD9:5OS" W^5D[YJ(W / )]-$!-$HD)IJGW!B?284\R,143_6%@>ACB.IZ-+J MY/1Q;\=-0!R=>.!51QYX!DB(.Z#\83. ;PO#-<6X+8#/*48<*AXHB_PP-L"D M8\9\@!7WJ20X, &.L345Q5BN,7I[C-9$XE%A?$XDK)4!%VXWFC!VRZ=MY$L; M 5,6(9? )B(4FYI(+ 0XQL)&441#S$(6DD!$,;'PG:(\,DBCFD@\,(#1-)$( M38280,PGQ%AWU /V(;AC/K78Q$)9S , L,M?_/=, G%EV?:;,L[WQ&Y-(&X+ MW',"$8::H8@)7X0Q LN+M2\%#GT%01%DSB'L &%](16B+M*;4Q\;$/E.<^"*(J2]E9+3!$J.(.P9!0SZ; M0ES9*>%-6>=[@K>F$+=%[CF%$%H&4:1BWQH$]C>6TA>8ACY2@6 DBC@V9$PA MZ-NF$'<":4TA'A7'YQ1"4LV%9M2E'JC/K $+[*BPL"9$EE!&C/K9%.+9; GY M .A7$H6AM2S4,6)QH 0F[L1K&2#%J$!QS2\>&-UDFE_HD#..E?5#X78H!#S[ M*D;%!03@PD%"HUCQBF.:"01(R0FF .IKHG$0P.83A,) M$H!)(1#D!<1ME&(8\15!L:\#I6-M0B%CYH@$F9.GX&_:.-\3NS6#N"UPSQF$ MV\!0;%?O&(NR&G)4O ;N^)$@P1#2N&'"MO^>J/Z6P(2:,?"%E[#.F MM"\B)'QM(Q>((\EYN#"3-,.[OF%O>T\PUXSPMDB>RBFY@_ 89C[&R(4RB/C2 MRL@W ?SB<62(.YBA5MZS5%X0!#*0$6B+,Z#S)&*^= /F(HRHQB8R*(XF='ZM MMCCW!6W-[Q\5U].'Y'(@\4'L:P609J'&?A0&;BYT(!35.A1N&++6[TO5;Z" MXH:(^W% L;-;;B".$3]45DD31U0R=(OXK8[G 'J8Q &1H0TTA>[#(JMY9!B7 M2%L=!KR.!QX8T'PZ'L "4\F9]6,I'*!CZ2LWQAQ)4(=;ZD^).]6[B>=EA,,W M[8WO"=Z:0MX6N><4DBH:13&)?&N-6WL$\)7$8#_$*@PH"JE"D\GO-49OC=&: M43PJC,\9!8VEC4.'8,O<&H[0^,JRP%? *%2D;:Q4/:1\S=Z<@8D"(->QE@%# M*A),A00C&IE ,\&BFD$\]#X2K75T-+;%1W^'@020!H$?1-6D" H4 D>Q;R6S M$ 8) C9GX>1W\:;-\SW16U.(6T/W^ RZ,8E#)"+CA\AM\F.T]67 X2-F-B*( MA:%D8PY1@_36(*TYQ./B^.0,QUPQ;4$_8'-#B.) )7X48NECHV.73Y*"1S6) M6(AP@DT<6ZZE582%)A J8K$*8FNDU)C3FD0\.(*_3)$(X \214KY) 3JP#"/ M?1&Y@Q*T$CBP6H N7!XBF).'H&][AY1[HK&[CF)0 !3V&J2W!VE-(AX7Q^4R$KO;R"?D<%O&VMP.\)WIK%G%K MZ)ZS"$JP5,@P7W BW62>".PNBOT0@FRC8Q0$;+R93PW2VX.T)A&/B^-S$J$B MS:6QS ^HTCXS;E,J$F"?42NC,+(HMG%-(A8BG&(BPB 6ED2*!5Q*082,(XGC M*"2ZGA/Q\ AN3\^)D,1B#&CU>4@0X%8%0(/=KCT&Z0";D(/A65HE33*/1,@W M;9_OB=Z:1-P:NN4 MUBSB<8$\-2G"45X<"%])=[R&1-Q7 1AB@3&/M9:$B'I2Q&*$6ZFMUH2 V&)& M0J,B%6I$#6$,$(_KM1D/C^#I21%QC)D,,?$YB8#]QL8"EH5R>_\9I) V)*P6 M9]0DXA' 6Y.(6R/WG$1H8:7D%OLHC-WZ7A;[(E8"F'!L% >E<#7)1,BWO:WP MG5!:DXC'!?(YB0#=*)<]\ZV;DN9R1;["RO@8 4G@$3\^*"$(>40$&& RR6V$4 M"5\QBR"JHT08;$@052QB'HEXVZF(>X*W)A&W1NXYB>"AC@R.K"^06T]$;>Q+ MQ8U/D8T,#3CCAH])1 W26X.TYA"/B^-S#B&UU(&2S$H;Z$BE M]:(33W[!#R^W^TE1YJI?>DGA014M-'@?.JBWGV='91<@ MWX.:GW@*7).-X17&2_K>SC"U'D/2A M_= XO\P&*W10/KI1F:V6S3DB/JOV#2NUEB1%&KUOS/SQ9[I'TA_108;;G9W>;@<,76>?;V^LH?;&X>GN 1BL@[4C,(6] MO[!^UH;A\=_Z\ $$*AC'P=N%(MH=VX!5WZ@C3L62)K(Y9_^^0]0 M"GL_SU ]!:ZO=KOG:!/C!5:N ;9MILE,XLO6L@L&T:96EV 0^UGIE9DW+&QU M%W0;VS?PO;NS $N6];T!U#8SKD]4[TI/W,N/$GBUZ_E]:!MV/I(#GP,RJ MOG:=6VF=#:%[P,U%J?I&Y:;P!GGV(W'E#X9Y,725@9>#U:Q>A.D[](W,N3IHP?@TCS9!#50;92.8KN4U5F?RP[X\24W8GC&[JP1&U M7$'GCZBHR-)A>?61^169_MG-SVGNOO6CW*I#7\7@E%94>J1.BJ7EB^X(?-&E MVM_VQ3<5TMCSC9L<5,ZOHC#GPLB-S7W 0ZH&A5V9_/'>),4@529E M>>%,YSK44P$QW8[C1-N\>.]MIF.+.'WK>V]M,,B2?MF#6--=N?J<8QZV7RBX M_<1;RW-G/]W=Q:S;FS,.EYX='LQ@H'PB;W Z\((5PBH3L/2\O&8E^.V^MV&U M[440-B#9<%N9HH;72L"]V-3[LPE2@_HX1YC$"7BFEC5EGH'G\#X/HQ1^?4IZ MB7.58U[GO7/NZ9__$(2@]^/OJD_X_2_@N13X5^L=9)%SNV62.Q\(/M<] M-_4 #M^[, %"!F?IO6^@%>]S;HO$211\JSG_U/#6P7TFV0]5Z&&JJ\P^QK2UQ;XHN6.'PL2_P41OC+,.HE13$V MK2U5 O(+1T&5]RTK*],\R5]Y?V2I<5=?9OYDVNIA?&;USFS;(-4-:/5@9.+2 ML8F;A/-9OJ_Z\#;C#<&^C](MJ3JJ_,B6XZ9@G!:8P0:80#!_"3@>]UYOK=\? M AW_:/LVA]\M:ZNPP$F[JW+;'4L:G%-E/D A*Y[W#O\RBE(:+J IG/MTP0V8 M1$=S085%PRN/; J&STQ\)%A#I;M.H:Y,>(%S=9Z+0M*J#5 ;O* V4P:ZLK^C M!UU^!MRT2SL50ZUM4<"GY"R$>N^]([]X4+S2#\6L^R@1/"IT^?Y_D*YVL'MC]R#T.30(NKJ"Q."NA< MWHD%QU"UT-5=#@8^Y0#D (;J23=G-L^%^MWILS;W9 M/0R0*:TK*P/ME*,FCFIU5F1N>T,G9:G;C'D2Y'(6C%<49%,A"]=3&H>WW5@K.7CR4 71EJ"+U^"%[*P0V(TCM^ MP\>R >AJ6.EKD%O?]@85+\M=3X-RJGX0_'(N["L01=4QRX4UMDF5OTZJM$KA_%#NS!MTBF.P'D?=I#)?[K5' M >7G4F=L(!7NO[24P]%P$KIRN7:TI=@UR;H9W#M"S&3;-5.PN7UZI:;2S8V1Z4,D;8Z%YG M/"N' >(?9(5+6H$FG3&#*V47^'N:':W<+;,SYD2^(T K-+@4+_E8/$4.OQ(= M;CY1IA7>_OZ"6#!J5D&C4V8QS00FVE[S63_7_ M#>>N(18#J!2WQ,JC!4\A"N\2/!':I"*X4_2T^!JG],%C,HR;DLF74EEX4-XM M+GT2R7)42_81*BN; ;I;J4^" A3RA\QY()<T M#UD^(Q%;2^=,.MZ[SS;7XZ#Y6\7JUE51_E)+;:[4UO95 KR^EM!U$JJQ=7O) M184;1JHE-%="O^?9H75SHON^@]2\8;8''B-X@DB\:NV.&TB#".R/)@16ILII M/'-L5,F[GQY[5\*2(6IPPAHA)[60Y@J)-@.*_KL6T#P!!4$#D: 1A*B6T5P9 M-6E88VB^?$A# HPPJ2$T5T08\T8@9"/$P2OWX>NY2O:]M;R?I:;&PUP\@-6E MT&6"AB"R%M-<]RV:'//:],['$6\P0AH!8;6,YLJHR42-H06=+! -)&HK5#OO MU2\Z*TMOO>EM9/V^3=.3&A0+/#BB#1+(1L#"6DSSC4N32U%;W[D"HKQ!*6IP MRFL9S951DR%28VA^)\-A@P9U^%U[\-6UOLFM;&[.6 MZ-3HF+ARRAJ"!@T>BEI,VK?L/;VMJJ@;' B6/20"* F'P6-&HQC6<- M-!FKX_$%@YG A%KL)#6,IHKHR;G=3R^H).Y<3U4 ZCVXJN3O2&VF]XGJWXD MY7.?2?O$+EPV,$8-R>O.LVA0').P-K_S<20;P'$:O)Z0M&A07(2TQM#\3L9% M P5U)J=VX:M_*E=6QSGPONVJ>DKZ@@PQ;P@.43BO(_!%(^)N+60MH'D"8J@1 MA+*!PGI=PX(1<4EJ#"V!FUX:_TH;7JN>D7Q.*APU& M9(/P>A1J82A>CV,NQ!$EI(%9'4DM"L7KZ12+YJ2[S5UHO<:U]N.K&[:?%!9< MM[<]/N/@DU5YO4I\P5PMW BX!'C4@YF+XO% UJN"%L2:K"$%J6=%+H['*:H7 M)RX:$1V[M 2$U*ZF3.@EE_#81X ]<;#-S+A]_ER,W7?W&BI[=^ MBORE[O ,SUPC3<\;'3!XX9RSZM30Q)TA]OS.#37/Y>#0!SO%>O51CEL#I#;1 M"*VW/6^-.^_#PH@IHLO&N%GJ2R-SL3JSZ\ZNY'G51'YCQS8O.4 M\IEYNM KSU,\TH%F8VL-;5N!>SU@*8GQ)HUY)3RX@21J$,8;H7R4E-_/DN%/ MZG+S!B;8[%G:KZF3O8P3WIYR*AMMB% V-0LYX5;7Q.\KC_MKX99):CVVL_%UY64X>VS1->DW9Z@H)^=MZ*S M\U9J,,BS'RY%E%W.6RGS(RFR_,2+5)$4HX21SGH#VR^J;(ZGCA2P4..R/[.2 M27W5@XOVV.JA2UU"Z!0G&MXY/PMT;S74>:$Z+U3GA>J\4)T7JO-"SY$Y228; M' +:D#_*UBAO(BN$F^'L!0.OJ8O56:%KYSPU L8;Z-FO<'S*OB*:9/;RK%?5 M5>JLT#4[NC4H$@TPFG56J,X*/=7+[=]>Z12%ZFX M;$TUU>*U2>N&1.4A3#<2E%TWM;V1K$R,M)@(0\?#F5K;,U=;;FJ>53 M9VM>7*[A:8=32=@0[K]\E+6?;R)?(YI2H%)PSR-]$ MND8VR>Q=0%Y3)ZO3-=?-'&D@SB .?>Y[G3QE5T'-.K0>E)475A7P*3^TI3<8YKJK"F@'/-"RILRS?J(]H*A)WQ5S M[?2=5Y#]P8*_G(1*<,=BZ^S/R^>/=?:GSO[4V9]'S_[@!N6\@=&C1*UO(OLC MFER*5Q_3UMF?Z[8";G 2-JBL)^LLFJS#$'GU7:5._URW*71 >0.Q1ST;I$[_ MO'68O?7TS\]]K-Z%^U[BZZE\'^HQ%D90(>HQDD?N^$E.[Y([@@?%_*MWS9N( ML"G)S8I]#"/^JRNCNV/UA.DK7?MCP-I)" MIUDQS*UWH9&+3C/XB3GH"G#;?6_#:MN+P)D">7=[P*,+.[R/UG0:3[D9@H7; ME3VUJK">ZO>S85\GU0;O%S:H;W@VCJVN=N[Z4_6'+J>,JY+A9Q9[7RPT\XM* M>R EM_W[4&L++V@ENJML=;;1>@8R<#O9;YYM ?8MT=;[##5(1EO8]\W4I^D\ M]ME$QW65FR3[H0H-*LF]SUE>QA!Y9TUOJ^\Y0#DU-2[EU*LVN8W)NJKT6GES M4L^C)$T!F?TRZ0^MJS4(P]2"?K_VD;+H\/XC-/6?S MHIL,/&AN?Q]NC*S.>G9*:/"^2W)K>FOP]L%9BO^B*I+"BX=Y/RFZ4/.CI'1; M[<-W'[*\YPG_7R-!=I,H*3TP?%#8]">7[H>V];,2*N(9:]W6:ZXU!&"7I+:: M.4KP^^JT@,$P!_\T&CGXXFH+5<5B4BOX9IB#6*U[WZAUWIJNU(,E!7!!153/ M'4)@O'?N@?%KIF\>O^T70$KN97!3?N1.KBR&T0&\;[)A7 I"3M+1JX907CY2 MV*1*#AVSF@5/PX>DKS-H!B@'OHI.0(RQS2VH':[ '0X(T'"GN$L#*I,W76CI M>0/I= .K^KM;IQMW=?^Z^T]3?BA/^WY60;7O?;V^5[XRWSLV:L5-?.V+[3SW M&/4DM,F"NPT6+BHV9$U*Y2OM/EPI"1NVT'DR6@5R MM1_]Q-Q1'#^: D>5,\"Z1F<+K51^W=T%=5*3ND#9VH<;13S&JOZOEYF!=#U3_+U>;V/\,DMVYDH+AQIMC= MM&/WDP+X.Q35585GANF)I]6PJ-+SB4M_#[*\'"=U"] /7("PU:6 (MM5:>R2 MNZZ@BGZ/;^C:W Y=FK3GKR1\/[Y#QR@]T\^/GJ/-!/E38IN M-@7\=BDHAAY^PP;2Q#?,7=WNF@SN5NK"_-VC2.#NY^__OX)?GW::FUU-C>\]>W6Y[7V[JR\_(.:S^ I;GTM@T,; MJK0KLY*U+P.CM=EYJV;G]Y.7TJ"G5=+3F9;E8MG[/59M/[9',H\D[# MM&^\.];-?XO-?\AEF$]KJ6L;4'>"NOD_S=<_Q>3\:C;6%]M/LOS2W/>&]]'V M;:Y2;ST;]@N;5M.=UR=3FEUN/;>ERD\NC6MK_!U!+ P04 " #F@XY1A)7J4PH$ #F& $ &UD="TR,#(P,3(P M.2YXT-7-L"&K.$T/G$ M_OIPC2[L#].SL\N?$/K^R_VM=<7B,@Y]8WQ M)_*,$9H:T"=6O' R?Y26[_KNYBP?A\,T3H;)#(7NT$=#;SA"4>(-$:3G01A[ M(PA<]^?YV/-=]R+T S3S74##,/ 0CL, 011ZD3=++[ W,J1+,1;Q(^384L*H M&"_%Q'Z4LA@[SF*Q&"R" >-S1[%YSO?/MU^,J5W;9H0^K5DO9SQK[ -'3\^P M@,8\3^2:=0Z)Y(R2>!"SW-%RE==18ZVYR YV0H7$-/Z;G3)*R[P;H-9QY$L! MCC)"R@HXB6T+2\G)K)1PS7A^!2DN,^5@2?\L<492 HD*;08Z>&L&*],2\SG( M.YR#*' ,AZB;GEF6WG22%XQ+BVYA4RQFQNE2H#G&A8)Z$7(]%'BV587JEL58 MFORK,49H)]"!3(IF!+54@Z5(;&>O,RLIX$51Y"QU3%]U8SM(QA[I1^3YQRW[ M6K0/7UN]H0;W3_C0YO-Q/C2X-_K0G<2'N+**O*N VI=(^^*='^B+81,0#^;L MV4F [,U+\1I(/[R:BIA2)@V+'JG'BH+0E%4#:DAOZ+C9U7M(FXJQ58\Z4M=\ MC3&/.:_$HED2\WJD+PW/#:EC;]>G^SXT(VSNPD M:19OEF_3=>JJ=DA]+-2V=RN/BLVJZ*P5ODMGDV6#OQ20_$ZGYGESEVIP;;(# MN%%1#L:MG\5.6#W81*$NS\YZ?:[>UVJXKN!U'V4BIS+HQQ>@A/$[)D'HB^"J M!-\-/-5-NW\ CY7E9\AGP%6/-A.2XUBU79*7*A7UO32Q#X93DJF#IK.R@INF ML9\ZK+'"J G- MTMY>FSH_ZJ.RXJWQU+_8K6X/Z+TU=6V^'QX?L!;3*T6^6WD7'*%H"],K12L' MY-P/WW3 MO&]4EK'8>@>'[L6\]Z*.H]_X)]0,UK0>VOJ/"W'U(PM3*\4U2=D M&!U_JEI,'Q7YWG7&U)IT?D)]W\+V46$0>8/P#5U'%[R/.OW '02CTZM_-[Z/ M2H/('_AO"FD7OH]*_=$)<1SU4E%=W\,3;NZP-S=WYW[ON;AW8_X]1>:'6_4W MWO3L+U!+ P04 " #F@XY1V($7Z(T! , P % &UD="TR,#(P,3(P M.5]C86PN>&ULK9)-<]L@$(;O_A54O7:%T$=M:2QGVK2=R8Q[<9M)KA*L+,82 M>(!$]K^O('$[Z>>E%YA='MY]EV5]=1H'\HC&2JWJB,5)1%!Q+:3:U]'MUT^P MBJXVB\7Z%<#]^]V6?-#\843ER+7!QJ$@DW0]N1-H#Z0S>B1WVASD8P.P"9>N M]?%LY+YW)$W2Y.=34Q5YQT4N6BB2/(6N/#F__1%_DCX""X8^!2P%#(6GZR(-@M"GI[#Z %WV!&_W^YN M7I0<43BCE>0QUR/U!+V,^)T2'Y63[GRC.FW&8'=N(4BZ\Q'KR,KQ.. EUQOL MZF@4#ORHYXF5WL?KO\K1'RYY,_"'(:2W<_PLZAW]/\-X65G2W7.HG+=BJI?6'ATI"F3')4 M,Z-8^OOM&9&VQ(L3<^!LD2_R< BB#\[I03=Z '__P^U\-OD#FK:J%^ M3& 1ZU0M+L]/?GW_([$G/SQ[\N3[?Q#R^[_>OIZ\J./-'!;=Y*(!WT&:?*RZ MJ\EO"=H/D]S4\\EO=?.A^L,3\FSXT45]?==4EU?=A%-.U[]MGBJ98Y(I$$4E M)Y))0UQBDD#60D5F0%#ZS\NGC%-J%1MNGDV9/)Y)XYW\2F MGL%;R)/EY:]O7VTBK1;=6:KF9\LV9WXV0\1##]W=-9R?M-7\>@:K>U<-Y)WH M5T/N0:D>SG=];V>C,5TAD";>!"!X%Q:]@Q?$N*WW\9@_]4429'\SZPHBWNR[ M*-YZ[JN2!&]T70#MT!&9PSQ 4Q+JHWX?X%R!7$?8=SF'U#7UHHJGL9Z?#?A6 M<^OS17JYZ*KN[M4BU\U\>/C_'.Y\@,0I3I5N@/7%[AZ@1'>H%E5_]S5^7/;9 M RJ'%VX[6"1()Y,JG9]4GGJ5'7%]3YQZSBCPH0$+O#I%WOND:^PS^KX MR-"LGROK3^+.?(#9<'>:H)IN](4#AE<=S-NI45Z8E!6A-#$B?BI M5A(2]YONT:[EG_<896T$>8ZR](?T$H6\ZRWWT9P;TB^XUK1==[;#O- M7-GH62#>1XNA4@*Q.N)( E/.8*R%6&(D#VT^QO[9GYXWJU$L'\$]G]$^L2BN M8E<7(/!>'01_,JF;!,WY"2TAY!MHJAI=/[W '&LJC54I4D6 "DID<)D$FCT) MEGI*#352EE3TD?&CD79_2C>Q[8-7>#2AFP+S\0*_PE54AT%_7- MHFON+NH$4QH8C0F]3LG@$9[!V8:A7#PQ0[W/3HX>8+4(Y$_G)T;WJ# M&.\-/U8S^/FFYV7JM8],1$V"0D 87@+..H81;G"]FW+PV=!BTG^V>R0Z[TGD MIJARO*CO_>VKA*&ERM7]"GT)3$0,+RX&(I171 J'<04'1S@@T)0 A%?%%-X! MXDCD+D'QIO9JO/;/4VJ@;9?_],-E4P#*E=:_-._KCXMIY#BD"!J]#T>**21F&(HKPH1-)C.& M::0HK?9G\\>E]9ZT;BIMRBE]GSY,C0DL>D\)E:S'PS7Q8-$1A71),"FS+2_S MO>TCTW@/0C<%ML4$?E.WG9_]M[H>,D0NE8_&6Q*]0-_C5A&7*&MTT<,P:7:"*2>A>,M)&% M$A'ZD=&#%W9_"K=43D:5Q_HP\;P!/SA5G^&SH##G2QF=RJI(O%>!:,C:)=!9 MLQ)5L8K!9S"2UK+B1A1J S&8=3A+2"8*@P M#/U-V")5ZW6[!Z_H*"*WJ#JJ\O5;4W4=+"[J^?QFL5RPM5-A0\Q>)DSA?#]C M.$>< 4>85"GY8'BB)2;=K<8/7M_QE&X1>51!ZUT]JR*2N+C\R7?05'XVS2 I MU7RHOQ@)K!4BA(/[Z;E@Y=W))E;M!U5UWK30.]IL(@PO [K M7]HVO^2,\XIDWO,(BH!/0&2FEEC**#@M2Y$[A;-1]6S MUF"]:ML;:!Z!LTZHOKB&H<43B>LT$BCM7ZIH#N"L"RJ45WX#Q['I/X[H+5XP MJLKU#N(-AIH[QL/[JIO!E$EOE+61Z" 00@B1!!$H$508P1G3N&E'$[I%X5'%JOLQOIQ#LYI@.I3PE^G/G+ M*;/),XFI?\@Y$"EYPOQ?&)*#M]Y2H,&6V!KRR.C!2[L_A5O$++"]ZP*A-'[V M"I.[V__ W51"IHA#$B48)O@XE1#'^C^:"^,BCQ+*;0E8,W[PXHZG=(O(X[=X M5="^]P$S/!-9D#DJPI3"#$]Y23S@"'G"Z!$R1:#%]@ZOC!84]<'AC;]'RKV( MV[8+WW^TB,KZ+162E3+9 MMV&09VGHWA5@UK6K.^L^\:>("OK(%P[3;/&9_02NOP71!3?OKH ]Q/-BF!#_ M$J+IVI&>DBZP":GDI+_K4-)GY0MK5G\3PO\>5PA111T5)6EX/QJU)BZE2+RU M3 ;&?6);-A("1GGKKI.UA4=?-SW4'; M"_#B!CCE[,=9[8>W-O?X!$LQ0W+$FDU43RPG(Q0"'5?D?FQBKL/ M>07/X^S$)>BI,.H-)K48JY88-4LRF@Q$)*EQ41,H<1028M0)6-: Z\I]!=YB M[_C$'DMJP:,W&Q@Y76)06/WNQT/+7$A4UEQ/! HC XV.$0KXJ4V&BEYIDKE?6^3[ Z-E''D%?P M3,U.9UOA8L9Z8P6F?(9CZ%#*$ZNL(51SI8.QTGQ]W%VS<3RBCB&OX,&9GV!V"=0/?*A#'KB*39$2 M/6&AKZ4+7-U;)H!X035&&*TH?+76:S:.1^ QY)4\B;/+\Z1; L-LD8J,2S]- M,R;,VN]Q-K=P-*+ H0!*> =TM MXR*@/Z!+#!>X]D./2^RK55VS<3RJCB%O]]F9[\_6B'F-'Y\]6=[N__3_??*S M)_\#4$L#!!0 ( .:#CE%[5PCF8!, C, 4 ;61T+3(P,C Q,C Y M7VQA8BYX;6S-76F/&SF2_=Z_(K=F%]@!S"J>2=+H]L!;=@^,==N&[48/MK$0 MF#S*0JND0DKEX]\/,W64CKR92N476U5%!B.>\D5&D$'RYW]\OY]%7VVZG"[F MOURA:W@5V;E>F.G\[I>KWS__"L35/U[\]-//_P' O_[GX]OHU4(_WMOY*KI- MK5I9$WV;KKY$?QB[_"MRZ>(^^F.1_C7]J@!XD7>Z73S\2*=W7U81AA@>_S5] MSJC3AIH$,$@QH(AR( VBP+J8,(VX)1 ^NWN.,(2"80(2#"V@C""@-"/ 2H8D M2IQ0B.="9]/Y7\^S?Q*UM)$W;K[,?_SEZLMJ]?#\YN;;MV_7WY-T=KU([VZ\ M5'*S;7VU:?[]I/TWDK=&4LJ;_*^[ILMI44,O%MW\Z[>WG_07>Z_ =+Y;3A?FTTJEJ[/!_G*UG-X_ MS.SV=U]2ZXK%SM+T0&JFIGNO:@7&[NN[YTK,+T M76_J?O;^P9Y?X;UA@E5>/U"OYV:H9WXK\=BL5*S 1Z+IV'V5)YE MOWCK/VV&R015.--\G(WKWE/5?E_9N;%K;WD@.IJ:7Z[\IXFQT\GK^6JZ^O'& MOQC3AT6:.V[OJU;V=O$X7Z4_;A?&3I!BB6%)#!P6"E!"K7]%Q0@83HWB!"O/=SXI>9_Y-EKW[Q,U< MW=OE@]IT\$IG0<+:CA=KE:,#G9]%N=;1(HTVFD>9ZC_?/-DAV\+SQ.6EMRS'9FGU]=WBZXV7Y#%",OL L@\ HDTH\K>F MH]R^%CK804.OJY$:[L/XCV;&K%UFXW;M_.73][XI3'^ 5C>^H_OT\^+;_YQQ-BXV%' MI.2 CZ+,DVS8"'3M6VT=0IHTP@K M"*9AHJIV"'4(HTHQ" Z=3B4/'"Z5FG8:(I4W[4CSJ5U^5LG,3HRQ1,B8 *,- M =3&#@B7.&!HPF),"8/&M"+W5O(H*>V5B_[,U6OXYCX%K"%YN\ P!&6;(-"> MIL?6AI)S)V]82AZ;<4+$DP;]9"44;N) *Z&SD!O@I(* 8FZ!(C !0G.%H""* M4!J2E6P'&ALYT37AK# KH3 LQ-Y!VRTKZ0+8A;(2"GO*2G:0A64E7:"[<%92 M\; %9R7'<+3,2G;=+YJ5'!M1EY65CCL^+LN*I'2([>H0*O%OZTWY0'-:U M(KGQ"T0^BS*]HXWBH8ZV M:./K"_C?@-@[NZ5ZP%KZJ K)%W&5]>;5NJV M&W1MGW!^6LRFVL?.\[O?E'>#4S6;$)M0R1,&G+(BA^;7W[2,-JJV#S[+$"O/@4-P^3<7K8%'*U2T7*K _+1 J&#):7E!NUG MIA6M B>!-_^]G$&R/5?5*X"(F^IH4/9%]F8KC(O-*I MX<+&'=[55C^F7NKK[_J+_W;M._^-3UQBJ8LA!$CRV#.?&R!P H$TG,8((\PX M:_RV+AA@;*3?ZAAME8PR+5N\LHM ;/#2#H3F[,E1*U3:O;DK3 ]Y=Q>)'>[M M76'4P?N[JEU["F>+1"]3J_)BKD0H(J 4@&DJ 25" R%]R!TG$*J$HIVA>#,U&QH?2M*%ID:0,4#<8-1L,B(?>H5_KT# MY19?;?HR6:Y2I5<328CE!#/ ?1H+J*0"*,0P4 8S$PNN,&K.N7W)HR-=IEST MH.[L=0O&'6#5@')=$3@WYW+C_]QJUM-J:J&U(;0[D#<<[XK,."!>88.NZ>JM MG7M!LS=S8[__K_TQX1@Y&',!,/,O/*I]TBH-M( 31 S7"C/9KJCA>(2Q,7&3 M?&VTC'(U(Z]GV_3T&,BFJ6D /,.DIRQTX#2TQZS0%+6O8 ME&TF0)8@UJHZH M'6FD]/;:1H?J1FM]V]*\#."F=.\!MF%HWQZQ#O2O02/8#93)']@=U)AYZA;J M.G1U#[].9W;SP!(.E6"< Z%X5KV(8Y! Q3R&T$FJL/*Q=CN/\"1\I$X@4[ C M[?> :\KT;G ,0^XF2'2@\ZG)P0S>$SDP:4^-.>5I09OVU-R>8_#9=YU(J%#L M8@HT8MFLDZ- :HN!P"3Q(%F'4..MF_N"QT;)W>$-F7+-V7B 53T3NR)P9A8V M,[X5 8LL#2#?@;C!B%=DQ#[I"O_>3UT<)C KI#VL**).6FUE J#&"/B7(@0* MV@0(J[.]CL:_0[O5%%<,.C:BPM+Z8DS":K@*(:_F]+F //OZ3W'5%B;/HESQ MGJOC"I$-*X\+1?C"]7$=D XND*N"K&6%7*&HBY;(51E75R-7V;=K:O/ZWJ9W MT_G=/]/%M]67V\7]@YK_F C,2!Q#"QRB%E"D?3@5^Z3'")@DV/](8.,%A8IQ MQN:T-V'^5M=HK6RTT;9M\E,,;=,\*!BP85*BMEAU2(\JD0C.E(JE#YPT59IX MFC]5-^\GLJ-R\P*,H8L=D@90FRWH&VHR7X!]<$68=:N^T5# MJV,CZL*ID_;=:Q<13CY/5S,[L231C&H.F+8:4,8H2*3 (#$*8B=P3&SS709' MPL?F'W.EHH6+$/[OY._15MWV18L[].I#HQ!,SNP#V\+1J5KQV.X>*A5W(@>O M4CPVIJA"\:1->Y*^]-[;9![\UYFZFSABB:#(@ABJ!%"G$9 ">H82AYFE3"#9 M:-/FB>2QT7.G7)1IUYR5AW#54[(S"&?F8T/[6]&PT-8 #A[*&XR A6;LLZ^X M03\G3[#M7G^B;8RQ-4!Q20#EL0(*:@F$(#;AB188*%*H1G[ MH4IQ@YX6M]&OLX7*MSEO%K91XIR+-4A\D@\HE0E03 L E9,^DJ$*QHW2^Z8# MCHVH6^VBC]E1UD5KVRAP!?88\6Y3I"$X7FBJ%*-GT0[>GI:SC\$,7,H. /72 MR]BMP U?P2Y!JNWJ];&8RZY*%XXP-B^\*X-;:QEY-:-,S_;E@(= U@=0P?"< MV;FV1J93K6"A]3T4#1[*';QZL-"LHC+"XH;M0ZZ7F1?<H3C@@&(H!QYK%AL:&4][V#JO3 M8<;F,U]O;US:J1K]F2D;Y=JV/7F]&-GZ\*@?O,[L,+M"U>E"JG(D>KB'JD#X MX-=/E1M8=.M41>NN3N"CO9MF9QK,5_F93X9BA6$B@)(T =0D"BCL!+#840RM MC9UJG P5#3!2XC\IV?+@K$(0FS*].S3#<+PI*AVH76QZ,*F/Q Y,YV*C3HE< MTJZG^^+()MST+^K$DUB A$D+*+8*2.0LL!1R)BQFL9-!]\61L>8_I??%==TY M=0QMRUGE ,"&G4U^NNR,]'5?' F;.PZ [M+WQ94_;.'WQ9%N$\/'W2][7QQI M.!%\.6N+0*>RIM#XA[BN4.%OA4 MFK4?^50W;$_E#ZG-9%FO8;XU/;O#.WWO7+;*+B1*9%;W@G6VX8AHG\-@#!Q" MC,8,,]A\"J-\F+&1VFL*])ZJT5K7*%>V.;#]HG9GEW8!J1?9Z' (8 M7R%\,-K7&[C/_0:MVSF QR6X4^IADDG-+N!>Z+\V828D)*8Q)\!)FEW300A0 MV2X:!I,8&^$PI8TV&Y:.,#;:OT_-=*[2']&G+\K+?1;]9Y[_H.A!I=%7-?.Q MZ(-_N)?97YMY@7)PJQU +Y"=F?MKW:)7M M;+7<_N:8^^6##$+[6ANWC*]OV(WLGWPFE_N/VYE:+M^[7/++[]/EQ$'.*#,4 M0.$LH$JA;-$W 9@1Q$TL=,(;7?=<.]+8R)_KE^T9VSS0F8X-$_9Z5)NQO1>L MSLWZ5C"U9GTM!'VROWRP0;U KA'=G>US5H6[&7N0'MR*C2R\^.V_43_!"$?/)_>/Z@140GV8P(53XEHDG" M@4RD!K$2B!HL[2W3!9(N>\MTN6FUMTQ7=.UI_P+!FP<> M6R(D]PDK83ISWIC[U)590'ALD6!$Z;C103.U(XW-6\-KSDK<-0XLQ=^!6^^D M>X/LS*ZYK/2>X+[V+^Q "]R_T 6\"^]?J'C@PO0=X]_0X"\: #L%3]#!'R";'@('(+P*&+@5DCW$@270=8A"CX1=?$P MN,RX)G%P:=_V\Y%O_3]20=04HH#HB %M#L?JS$. >,<5I!RA/. M&U=P'0L?FWO.]8MR!5M?DG4"7/WT8P@<9W:R+9!H->M89G+ C..)R,%F&\N, MV9]I+&W34Z0E\35FQ_,S'"%*N0$"92<79T>BBH0YX""GBN-8.!QTM%'1H&.C M.1[(>0=(ZU ("\5:NE8V\ME&F;L?5X$-D6ZX)=\9KX)7AIE!U M7R$N1**O=>)#X9=9+2XTL'3-N+AU3V5SVTE>!J%#VB5 Z^R(2L-%Y@8TE \Q-E=QO!UGK67+?4L%2%;[A'[P.;,G: M-^QV*I=;WND7Q=)1A M]RB66GFR2;&\94^)%=\F5L0B9+@!G#D'*,$&*"42D&#F@P0=$Z+#+K7GXTRL MT#4JVY#$ ],$'I99=0#L4ID5[RNSXOUD5AV@NW1FU0#"\,R*AV56?!29%6^9 M61VW;Y]9;79#9.?B^:<1&2B)3AA04B> 9E>E"!-SP C$,9%8R5@W3:,.)(_- M-6Z4B];:-<^.#N&J3X4Z@W#N:*>9_:TRG$); ]*90WF#Y2Z%9NPG*L4-RJBW MC^U;_^G%3]O?^'\2M;0O?OHW4$L#!!0 ( .:#CE%UX2=:[PH %!A 4 M ;61T+3(P,C Q,C Y7W!R92YX;6S5G-MRVT82AN_]%%SE=D>:\\$5>\LK MVUNJ=1*7K512>\.:0X^$,@FH0"B6WGX;$)E8E.Q0)&B -SJ00W3W/Q][>H9- M_/BOF_EL\@?4BZ(J7QRQ8WHT@3)6J2@O7AS]>OZ6V*-_O7SV[,=_$/+[OS^\ MF[RNXO4,4VH5%R1P"D0J MP8B/2A!PBCD6LO7,=!>=%>6GY^V/X!#*1??OBZ/+IKEZ?G+R^?/GXYM0 MSXZK^N($KRI.5J./EL-O'HS_++K1S#EWTCW[Y]!%\=A O"P[^?VG=Q_C)U_9#6,M \1QHE@QS>+=/3RV61R M)T==S> #Y$G[^]MZY MBR%TEVQNK^#%T:*87\U@]=AE#?G%T3PUI)UJG#'7^O'#-R]W\I>75S4L<%CW M^#M\8'G5UJ7^/(:;!LH$=^JL+,^J>&_0K)V;JEZ]P^) M$8X2F9 I9.I[\/Z>T?O>?SGKK^HXJ>H$-2:BE55?QP<$W'\3+$><7/D:+T3B M93%+JU>W&:F/F6NJ/A2\FQ_T]VB"86>H:TCO[J;GJ]%UH368GZ$;N>W47R_( MA?=7TX^H-+1OE=.97RQ^R1^;*GYZ=5,LIB8DEXSV)*L@,!##B(NZR[7>:1&5 M]?0A"BL2LE^$SNFEH3L<8-8L5H^L<_&W'@W'R0XS7.U#[A%P\Z7_KZNY+\II MB"KJJ"A)W@HFR,AP1IU5J((P%HLX'8G.0@8P.6<6]D+,NB?# K/KU*Z3LI/. X*" ME>+T(Y1%5?]<-;!H)^_U-6#MR-[.*IR-\F(9CV I9DB.6,XID3QK8B%& MQY MF[WR/K._*4(WM;41&7SD9.Q%V#&"PE? >^,=PUVCA,P0>,P"7EI-% \L)R,4 MAK8M(/P)8(A#!6,;(<<(A*#'PJCW4$<4=1F3QH(^F@Q$)*FQS@^4. H)8]() M6-8@C-L6CD?L;02*/%10=A5X3-!PNHQI&8WO%=&#:\FTS MA'D"$/;0@-A%R(&!>-5.WQ?!W 5BEX$8':SV0A,LESU6T!&(%3H0U HX[JT@ M6+D!$=\TLA$2[@"0Z$_*$28)P=@QIK.U6EDZ@2AGPIAU1-+LB)-8-?/@#0;D M%+YBRX3QF+W-#KKH :"R%X5'2@VE]T/**40+61'N-"9'(3*NEH&3@'\F<,Y% MM@LT:^8V8V;LIZ/[TG>,BX]8'=^P!(%S+E"9)(DTH# 0;0@8K+:T4=:#W7;Q M$4\Y"&.'<$3:GY9CS"..'W.U!CINO8W)&G,CEN*HE*<$Q3-$ Q;>3$'R=MMS MTL?L;8;*H1Z:[JSP**EAQ^LA41T<:!])=*SMD\""+,ADB:!8C0GN%?!MST\? M,;<9,X=Z?KJKOF-"9KFGE_3//;URCF=/6&@_3!*9$32+>/ 2IR*C/MY37$=1:8EEN*"8S F&2RZ/%-BR\RQ MLK$9$8=Z@+J5DF,B8DFV6I$-%%@4( G/@&1GW)R%]C38<($;>H0[L2<3L69C M,R(.]01U*R4').+/=KHO6W+?%26<-3!?3(WRPB3<>5&:&*Y],1.GVQ;PB)63 M5A(2[ZW_]%$/ANGWZ*?)L$=M!R9DU;]]CF.GF2L;NX^(?+0HA01B=42_ U/. M))D@]L'$ES8';C7M8?ZJ'L0<"018'1=5>E.FU[Z!J316I4@5 2HPSP672:!8 M&@5+/:6&&BG[I.&>\8&3PWZPV%[>42PC'^"B:!OXR^9G/X)6U-\Y 3+RW!>2^[6$ZPO9$Q\[BC@*.LS)6]555=Z)T?=FGU779 MU+>G58(I#8S&A(0K&3R&8S K,IQJGIBAWF>G _18;'S#E6%ZQ/:*3G_2CX*D MM\4,?KZ^:U[1/C(1-0D* \ E-&!V-%B:&159RL%G\\@78[;$YB^[P[2*[961 M+44=!1#G_N8LH7!%+NZ^N+D,1$1<0ET,1"BOB!0.UTX4@W# P%("$%[U1L=7 MG!BFB6ROJ/0A]RBX>942SL=B^:N5ATT!*%=:^5E5YG'Q,HI_OE+?5Y]+J>1HP01='L(K-KR'"LPQ15APB:3 M&<,27?1-RE_FAVD]^QZ<;"GQJ"BY*Z^FQ@06O:>$2M;ZSS7Q8!%Z(5T23,IL M^T?DSO8P?6C?A8\MQ!T3'.^K1>-G_RNNNNJ;MVWWQEL2VP\7);>*N)0SH3YI MJ5-&\!_YINYNB-SS8* VM.]!RO9*#\S+$O%VRU]A%A0L0;1 7/<9!<>2RB6: MB*3>!2-M9*&/DN2>T8$:S?9$Q?9Z#@U""W,-O@.XW7JQH+"@3AD!MBH2[U4@ M&K)V"736K(_CUB]M#M10MB\,ME5S8 K>X;.S]Y=5N=JA)W14X'K'>0:UL(YXW7Z=W&9O$U@J11])XZ'E@3K#]H3&CLH.S,7[&EJH MH8S=;7'.VQNNU;_DW/8Q,>]Y!$7 )R R4TLLY91DL#IC,H3,^SA+_[H' _6+ M[8F3GI0>%R]GB\4UU/=BL4ZH]I075T]/)&Z^2:"T_412 M^#%09]GW86B2!>XVIZRW@X+YH93)GT1ED;B0X"/0XADB ")8(*(SAC M.O>RG5VWNQDAAW)BNI.J Q-Q7OOV%K8?;^>AFDVQGG*X\98D@6F_7ZL[B@.S=_,H;Y NO]35Y^;2UP5 MKWQY.U4Y\;L;-U)/$7+&L/9N;XZFNAO$*EP =0^0?,.%S5@YE /2OK0>&)E7 M6"VEMF)Z._,74V:39Q)W9"'G0*3D";=EPI T8WP^)0#DRW MUW,4N>,4/:_][ SKYIO_PNU40J;HMB1*M-_FPXQ''&M_:"Z,BSQ*Z*\?:,WX M9F ,/0L #=; 4 " 9)! !M9'0M,C R,#$R,#E?9&5F M+GAM;%!+ 0(4 Q0 ( .:#CE%[5PCF8!, C, 4 " M 0%- !M9'0M,C R,#$R,#E?;&%B+GAM;%!+ 0(4 Q0 ( .:#CE%UX2=: M[PH %!A 4 " 9-@ !M9'0M,C R,#$R,#E?<')E+GAM 7;%!+!08 !P ' - ! "T:P ! end